The diagnosis and treatment of human diseases and the development of new drugs increasingly rely on our ability to determine patient genotypes using accurate and sensitive pharmacogenomic tests. Many PCR and next-generation sequencing (NGS) based assay platforms are currently available.
However, the type of DNA sequence variants, the number of targets, and the sensitivity requirements are highly diverse in different studies. Here Dr. Peter Zhang describes the design, performance, and regulatory considerations of several assay platforms that are accurate, high throughput, cost-effective and customizable. These platforms provide high-quality pharmacogenomic data ideally suited to meet the needs of individual studies.
Register to gain access to gated resources.
Thank you for registering!
You may now view the resource below.
In this eBook, we navigate the landscape of biomarker discovery through genomic profiling, exploring technologies, methods, and applications. We hope this collection of articles creates an appreciation for the wide scope of using sequencing assays for biomarker discovery, drug development, and beyond.
Frontage develops a full validation of the XTMAB-16 NAb (neutralizing antibody) assay with acceptable drug and target tolerances to guide future clinical trials.
Frontage supports early drug discovery with various immunoassays for proteins and therapeutic antibodies to support pharmacokinetics/toxicokinetics (PK/TK), pharmacodynamics (PD), and biomarkers analysis.